Clostridium Difficile Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole ’s Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection
Oxford, UK, and Cambridge, MA, US, 7 October 2019– Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced the presentation of new data that explain the link between two key findings in the Company’s Phase 2 clinical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 7, 2019 Category: Pharmaceuticals Source Type: clinical trials

Bezlotoxumab - in " Real Life " - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Condition: Clostridium Difficile Infection Intervention: Drug: Bezlotoxumab Injection [Zinplava] Sponsors: Fundacion SEIMC-GESIDA; Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2019 Category: Research Source Type: clinical trials